Results overview: Found 4 records in 0.02 seconds.
Articles, 4 records found
Articles 4 records found  
1.
17 p, 1.3 MB Clinical implications of intratumor heterogeneity : challenges and opportunities / Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sesé, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Capdevila, Claudia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Aasen, Trond (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Diaz-Cano, Salvador J. (King's College Hospital) ; Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, and protein modifications that drive phenotypic selection in response to environmental pressures. [...]
2020 - 10.1007/s00109-020-01874-2
Journal of Molecular Medicine (Berlin, Germany), Vol. 98 (january 2020) , p. 161-177  
2.
30 p, 7.5 MB The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Sammut, S.J. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Ross, E.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Bashford-Rogers, R. (Department of Medicine. University of Cambridge) ; Greenstein, E. (Department of Immunology. Weizmann Institute of Science) ; Markus, H. (Mayo Clinic Center for Individualized Medicine) ; Morganella, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Teng, Y. (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ; Maruvka, Y. (Massachusetts General Hospital) ; Pereira, B. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Rueda, O.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Chin, S.F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Contente-Cuomo, T. (Mayo Clinic Center for Individualized Medicine) ; Mayor, R. (Centro de Investigación Biomédica en Red de Cáncer) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Ali, H.R. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Cope, W. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Tiezzi, D. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Dariush, A. (Institute of Astronomy. University of Cambridge) ; Dias Amarante, T. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Reshef, D. (Department of Immunology. Weizmann Institute of Science) ; Ciriaco, 0000-0002-1151-554X (Hospital Universitari Vall d'Hebron) ; Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ; Vassiliou, G. (Wellcome Trust/MRC Cambridge Stem Cell Institute) ; Getz, G. (Massachusetts General Hospital) ; Nik-Zainal, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Murtaza, M. (Mayo Clinic Center for Individualized Medicine) ; Friedman, N. (Department of Immunology. Weizmann Institute of Science) ; Markowetz, F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Caldas, C. (Breast Cancer Programme. Cancer Research UK Cambridge Cancer Centre) ; Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10  
3.
14 p, 4.6 MB Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases / De Mattos-Arruda, Leticia (Memorial Sloan Kettering Cancer Center) ; Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ; Piscuoglio, Salvatore (Institute of Pathology, University Hospital Basel) ; Gonzalez-Cao, Maria (Hospital Universitari Quirón Dexeus) ; Lim, Raymond S. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; De Filippo, Maria R. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Fusco, Nicola (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Schultheis, Anne M. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Viteri, Santiago (Hospital Universitari Quirón Dexeus) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Macedo, Gabriel S. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ; Gomez, Patricia (Vall d'Hebron Institut d'Oncologia) ; Teixidó, Cristina (Hospital Universitari Quirón Dexeus) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Tresserra Casas, Francesc (Hospital Universitari Quirón Dexeus) ; Weigelt, Britta (Department of Pathology, Memorial Sloan Kettering Cancer Center) ; Cortes, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630  
4.
12 p, 2.2 MB MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Bottai, Giulia (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Di Tommaso, Luca (Division of Pathology. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Giovannetti, Elisa (University of Pisa. Cancer Pharmacology Laboratory. AIRC Start-Up Unit (Italy)) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Losurdo, Agnese (Division of Oncology and Hematology. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Pérez-Garcia, José (Vall d'Hebron Institut d'Oncologia) ; Masci, Giovanna (Division of Oncology and Hematology. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Corsi, Fabio (University of Milan. Deparment of Clinical and Biomedical Sciences "Luigi Sacco" (Italy)) ; Cortés, Javier (Hospital Universitario Ramón y Cajal) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Calin, George A. (The University of Texas MD Anderson Cancer Center (USA)) ; Santarpia, Libero (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Universitat Autònoma de Barcelona
Patients with primary HER2-positive breast cancer benefit from HER2-targeted therapies. Nevertheless, a significant proportion of these patients die of disease progression due to mechanisms of drug resistance. [...]
2015 - 10.18632/oncotarget.5495
Oncotarget, Vol. 6, Num. 35 (October 2015) , p. 37269-37280  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.